Tlando (LCPN 1021) safety data for treatment of testosterone deficiency presented at 111th Annual Scientific Meeting of the American Urological Association (AUA).- Lipocine Inc.
52-week data for Tlando (LCPN 1021) from LipocineInc., were presented for the first time for during the 111th Annual Scientific Meeting of the American Urological Association (AUA) from May 6 to 10 in San Diego suggests this testosterone therapy generally is safe as the testosterone gels and injections as well as the buccal and pellet products that already are on the market in terms of cardiovascular, liver and other systemic effects.
Comment: The main benefit for patients is the convenience of a twice-daily oral pill versus a daily topical gel or periodic injection which are the most popular forms of administration. Unlike gel testosterone products, such as AbbVie Inc.'s AndroGel, Tlando has no external safety risk of transference to a pregnant partner or a child if they touch a man's body where the topical formulation was applied.
Comment: Prescription Drug User Fee Act (PDUFA) date at the FDA for Tlando is 28 June 2016.
.Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins